Intellia Therapeutics, Inc. (NTLA)

Nasdaq Pharmaceutical Diagnostics SIC: 2835
D
Pipeline Grade

Financial Position (from SEC Filings)

$134.7M
Cash & Equivalents
$117.4M
Quarterly Burn Rate
3 mo
Est. Cash Runway
$1,878M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (0 Assets)

No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.

Upcoming Catalysts

No upcoming catalysts detected for this company.

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT06634420 HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE) PHASE3 Active Not Recruiting 80

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for NTLA.

SEC EDGAR Filings

All SEC filings for Intellia Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.